Targeted Oncology Staff

Catch up with the latest in oncology news from this week with this edition of The Targeted Pulse.

During a live event, Steven I. Robinson, MBBS, discussed desmoid tumor statistics and management for symptomatic progression.

During a live event, Kashif Ali, MD, reviewed the efficacy and safety of the NAPOLI 1 trial in patients with pancreatic cancer.

During a live event, Tian Zhang, MD, MHS, discussed options and recent trial data for treating metastatic hormone-sensitive prostate cancer.

Discover the latest breakthroughs in oncology, including FDA approvals and innovative treatments reshaping cancer care for patients and clinicians alike.

During a live event, Misty D. Shields, MD, PhD, discussed using G-CSF and trilaciclib to mitigate chemotherapy-induced neutropenia in SCLC.

During a live event, Nataliya Mar, MD, discussed systemic therapies such as lenvatinib/pembrolizumab in advanced renal cell carcinoma based on recent trials.

During a live event, Nathan Denlinger, DO, MS, discussed outcomes of the ZUMA-7 trial in diffuse large B-cell lymphoma.

Discover the latest breakthroughs in oncology, including FDA approvals and innovative therapies reshaping cancer treatment landscapes.

During a live event, Tony Philip, MD, recommended tailored imaging intervals and avoiding surgery and radiation for desmoid tumors.

During a live event, Matthew Lunning, DO, and participants discussed the process of determining if patients with DLBCL should receive second-line CAR T-cell therapy.

During a live event, Jorge Monge, MD, discussed real-world evidence on the use of CAR T-cell therapy beyond the trial setting in multiple myeloma.

During a live event, Barbara T. Ma, MD, MS, examined trial data on lifileucel tumor infiltrating lymphocyte therapy in patients with advanced melanoma.

During a live event, Andrew H. Lipsky, MD, and participants debate BTK plus BCL2 inhibitor benefits, barriers, and optimal patient selection for CLL.

During a live event, Sumanta K. Pal, MD, discussed lenvatinib dosing and tivozanib efficacy for patients with metastatic renal cell carcinoma.

During a live event, Hans Lee, MD, and participants discussed potential approaches to modifying frontline multiple myeloma therapy.

In this week's Targeted Pulse, we cover new FDA designations for cancer drugs, advances in targeted therapies, and key discussions on trial access gaps.

July marks a transformative month in oncology with the FDA's groundbreaking approvals and updates, enhancing treatment options for various cancers.

During a live event, Nathan Denlinger, DO, MS, discussed bridging therapy and patient barriers to CAR T-cell therapy.

This week: FDA issued CRLs for RP1 and glofitamab; CB-010 shows promise in lymphoma; osimertinib plus chemo extends NSCLC survival; and TNBC research aims for safer treatments.

During a live event, Mark Yarchoan, MD, and participants reviewed adverse event management for 3 different combination regimens for hepatocellular carcinoma.

During a live event, Bruna Pellini, MD, discussed the efficacy of cemiplimab in PD-L1-high non–small cell lung cancer.

During a live event, Jahan Aghalar, MD, discussed the efficacy and safety of darolutamide plus ADT in mHSPC in the ARANOTE trial.

During a live event, Christine Bestvina, MD, discussed trials of KRAS inhibitors plus immunotherapy in patients with non–small cell lung cancer.

During a live event, Bruna Pellini, MD, discussed IO monotherapy as a first-line option for non–small cell lung cancer with high PD-L1.

During a live event, Mark Yarchoan, MD, and participants discussed their impressions of the CheckMate-9DW trial data in hepatocellular carcinoma.

During a live event, Christine Bestvina, MD, reviewed outcomes from the phase 3 KRYSTAL-12 and CodeBreak 200 trials in the KRAS-mutated non–small cell lung cancer population.

Discover the latest breakthroughs in oncology, including pivotal FDA decisions, promising therapies, and new treatment options for multiple myeloma and ovarian cancer.

During a live event, Tony Philip, MD, and participants discussed molecular profiling and active surveillance for desmoid tumor management.

During a live event, Matthew Lunning, DO, and participants discussed how identifying primary refractory and early relapsed DLBCL matters for using second-line CAR T-cell therapy.